Get the Stockscreener App
6.17
161.44%
3.81
After Hours:
5.93
-0.24
-3.89%
Cervomed Inc stock is traded at $6.17, with a volume of 156.57M.
It is up +161.44% in the last 24 hours and up +183.03% over the past month.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$2.36
Open:
$2.4
24h Volume:
156.57M
Relative Volume:
56.50
Market Cap:
$50.93M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.1015
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
+185.65%
1M Performance:
+183.03%
6M Performance:
-63.66%
1Y Performance:
-64.88%
1-Day Range:
$2.37
$6.84
1-Week Range:
$1.92
$6.84
52-Week Range:
$1.80
$26.38
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
6.17 | 50.93M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
Chardan lifts CervoMed stock rating to Buy, targets $14 - Investing.com India
CervoMed upgraded to Buy from Neutral at Chardan - TipRanks
Washington Post columnist who resigned over a spiked Bezos op-ed ‘fears’ readers can’t trust opinion writers - CNN
Flying is getting worse, if you can believe it - CNN
EU's tariffs will be 'devastating' for spirits sector, industry says - info-mods.com
The maker of Roomba has ‘substantial doubt’ about surviving - CNN
CervoMed (NASDAQ:CRVO) Given New $15.00 Price Target at Roth Mkm - Defense World
CervoMed Inc.'s (NASDAQ:CRVO) Price Is Right But Growth Is Lacking - Simply Wall St
China's commerce ministry meets with Walmart on supplier pricing, state media says - Yahoo Finance
CervoMed’s (CRVO) Buy Rating Reaffirmed at D. Boral Capital - Defense World
CervoMed Shares Business and Financial Updates Online - TipRanks
Ontario premier threatens to ‘shut off electricity completely’ for US if trade war escalates - CNN
Brookline raises CervoMed stock rating to buy, sets $16 target - Investing.com
Mineralys aims to raise $250M; Coherus discloses layoffs - Endpoints News
Brookline raises CervoMed stock rating to buy, sets $16 target By Investing.com - Investing.com UK
Trump administration backs off mandate addressing housing segregation and discrimination - CNN
Trump says he’ll buy a Tesla to support Elon Musk, whose companies are struggling - CNN
Brookline Capital Upgrades CervoMed to Buy From Hold, Price Target is $16 -March 11, 2025 at 08:46 am EDT - Marketscreener.com
CervoMed price target raised to $15 from $7 at Roth MKM - TipRanks
CervoMed reports positive results from dementia trial - The Pharma Letter
Dementia drug neflamapimod shows positive phase 2b trial results - PharmaTimes
What Trump actually wants from tariffs - CNN
Who is Mark Carney, the crisis-handling former central bank governor turned Canada’s next leader? - CNN
China unveils big plan to fix its ailing economy and transform into a high-tech power - CNN
CervoMed announces results from extension phase of RewinD-LB study - TipRanks
CervoMed Reports Positive Phase 2b Trial Results - TipRanks
CervoMed Inc. Reports Positive Results from Extension Phase of Phase 2b RewinD-LB Study for Neflamapimod in Dementia with Lewy Bodies - Nasdaq
CervoMed Announces Positive Results from the Extension - GlobeNewswire
CVS is opening smaller stores that only have pharmacies - CNN
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints - Yahoo Finance
Analysts Set CervoMed Inc. (NASDAQ:CRVO) PT at $37.43 - Defense World
Here's Why Associated Banc-Corp (ASB) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
7-Eleven’s Japanese owner appoints American CEO to fend off $47 billion takeover bid - CNN
Walgreens is going private in an up to $24 billion deal - CNN
Camping World Holdings' (NYSE:CWH) Dividend Will Be $0.125 - Yahoo Finance
The US Postal Service is more efficient than you think. Privatizing it could cause problems for many - CNN
Musk’s Starlink gets FAA contract, raising new conflict of interest concerns - CNN
MSNBC announces major lineup overhaul, new Washington bureau as Joy Reid exits company - CNN
CervoMed (NASDAQ:CRVO) Raised to Buy at D. Boral Capital - Armenian Reporter
Why VNET Group, Inc. (VNET) Went Up On Thursday? - Yahoo Finance
Boral Capital raises CervoMed stock to Buy, sets $10 target By Investing.com - Investing.com Australia
Why CervoMed (CRVO) Is Advancing Today - Yahoo Canada Finance
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Boral Capital raises CervoMed stock to Buy, sets $10 target - Investing.com
How Are Things Looking For CervoMed Inc (NASDAQ: CRVO) For The Short Term? - Stocks Register
Why VNET Group, Inc. (VNET) Soared Last Week - Yahoo Finance
CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average PT from Brokerages - Defense World
Why Millrose Properties Inc. (MRP) Went Down on Monday - Yahoo Finance
Perigon Wealth Management LLC Makes New Investment in CervoMed Inc. (NASDAQ:CRVO) - Defense World
CervoMed Provides Update on Neflamapimod DLB Program as - GlobeNewswire
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):